Earnings and Growth Analysis : Bio-Path (NASDAQ:BPTH)

Earnings results for Bio-Path (NASDAQ:BPTH)

Bio-Path Holdings, Inc. is expected* to report earnings on 03/10/2021 before market open. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.78. The reported EPS for the same quarter last year was $-0.72.

Analyst Opinion on Bio-Path (NASDAQ:BPTH)

1 Wall Street analysts have issued ratings and price targets for Bio-Path in the last 12 months. Their average twelve-month price target is $10.00, predicting that the stock has a possible upside of 55.04%. The high price target for BPTH is $10.00 and the low price target for BPTH is $10.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Bio-Path has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $10.00, Bio-Path has a forecasted upside of 55.0% from its current price of $6.45. Bio-Path has received no research coverage in the past 90 days.

Dividend Strength: Bio-Path (NASDAQ:BPTH)

Bio-Path does not currently pay a dividend. Bio-Path does not have a long track record of dividend growth.

Insiders buying/selling: Bio-Path (NASDAQ:BPTH)

In the past three months, Bio-Path insiders have not sold or bought any company stock. Only 1.80% of the stock of Bio-Path is held by insiders. Only 4.41% of the stock of Bio-Path is held by institutions.

Earnings and Valuation of Bio-Path (NASDAQ:BPTH

Earnings for Bio-Path are expected to grow in the coming year, from ($3.04) to ($2.20) per share. The P/E ratio of Bio-Path is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Bio-Path is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Bio-Path has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

More latest stories: here